



News Updates: October 17, 2013

OPPI

Publication: Express Pharma

Edition: Online

Date: 17.10.2013

Headline: [OPPI awards at 47th AGM](#)

Synopsis: Organisation of Pharmaceuticals Producers of India (OPPI) at its 47th annual general meeting in Mumbai announced a host of awards in various categories. With the aim of encouraging innovation in India, OPPI has instituted, as Public Private Partnership initiative along with NIPER and CSIR, OPPI Scientists and Young Scientists Awards. The awards were set up to encourage original research and innovation in the field of pharma sciences in India.

Fire in the Blood

Publication: Frontline

Edition: Online

Date: 17.10.2013

Headline: [Indian generics and AIDS](#)

Synopsis: Frontline magazine has published a report online on the documentary Fire in the Blood. The report is based on an interview with the director Dylan Mohan Gray on what provoked him to make the documentary and highlights how Western pharmaceutical giants and governments blocked access to low-cost AIDS drugs in African countries in the mid-1990s, causing over 10 million deaths.

Clinical

Trials

Publication: Pharmabiz

Edition: Online

Date: 17.10.2013

Headline: [Notices sent in 235 cases as authorities inspect 577 clinical trial sites](#)

Synopsis: With the clinical trial sector coming under the scanner of judiciary, the regulatory authorities have intensified the monitoring of the clinical trials in the recent past and notices were issued in 235 cases. The regulatory authorities have so far inspected 577 clinical trial sites in the last few years and notices were issued to the investigators/sponsors/ethics committees seeking clarifications in 235 cases, according to the figures compiled by the Health Ministry.

FDI

Publication: The Economic Times

Edition: Print

Date: 17.10.2013

Page: 17

Headline: [Ban likely on non-compete clause in pharma M&A, may be a 'deal breaker'](#)

Synopsis: Multinational pharmaceutical companies keen to acquire Indian drug firms may no longer be able to forbid them from making and selling similar generic drugs in the domestic market by inserting a 'non-compete clause' in their merger and acquisition agreements. Most stakeholder ministries have backed a Department of Industrial Policy and Promotion (DIPP) proposal recommending a ban on 'non-compete clauses' in brownfield pharma deals in the country.

Publication: The Economic Times

Edition: Online

Date: 17.10.2013

Headline: [FIPB to take up Tata-SIA, 29 other FDI proposals on Friday](#)

Synopsis: The Finance Ministry will take a call on Singapore Airlines' proposal for tie-up with Tatas to set up a full-service airline as well as 29 other foreign direct investment applications on Friday. Among the other FDI proposals, eight are related to pharma sector. These include, Castleton Investment Ltd, Mauritius - GlaxoSmithKline Pte Ltd, Dastag UK, Perrigo API India Pvt Ltd and Intas Pharmaceuticals.

FDA

Publication: Pharmabiz

Edition: Online

Date: 17.10.2013

Headline: [Gujarat FDCA cracks down on retailers for selling medicines without license](#)

Synopsis: As part of its ongoing drive to curb unauthorised sale of psychotropic substances, narcotic and addictive drugs, Gujarat Food and Drugs Control Administration (FDCA) raided a Bharuch-based retailer recently for illegally stocking and selling cough syrup containing highly addictive Opium based derivative named codeine phosphate manufactured by Cipla under the brand name Rexcof. The owner of the shop Mahendra Sinh Sindha has been arrested by the police on the basis of FIRs filed by the state FDA. The retailer has been arrested prima facie on the grounds of stocking medicines illegally at unauthorised location without a valid license in violation of Section 18 (C) of the Drugs and Cosmetics (D&C) Act, 1940.

General Industry

Publication: Business Standard

Edition: Online

Date: 17.10.2013

Headline: [Investor concerns on Wockhardt](#)

Synopsis: Will Wockhardt be the next Ranbaxy? This is being asked in the backdrop of the company being under the scrutiny of both the American and British drug regulators. First came an import alert from the US Food & Drugs Administration (FDA) and Britain's Medicines & Healthcare Products Regulatory Agency (MHRA) on its Waluj plant. Last week, MHRA withdrew its earlier GMP (good manufacturing practices) certification for Wockhardt's Chikalhana factory, where the FDA had earlier reported quality concerns. That plant makes metoprolol, a generic version of the heart pill, Toprol-XL, sold by AstraZeneca Plc. It makes for a large chunk of its US revenue.

Website: The Financial Chronicle

Edition: Online

Date: 17.10.2013

Headline: [Foreign investors raise stake in pharma firms, dump Wockhardt](#)

Synopsis: The initial shareholding data available on the Bombay Stock Exchange (BSE) showed that foreign institutional investors (FIIs) hiked their stake in at least 15 pharmaceutical firms, including midcap companies such as IPCA Labs, Aurobindo Pharma, Strides Arcolab and Biocon during the September quarter. Wockhardt was among few exceptions where FIIs pared stake by 2.80 percentage points to 7.58 per cent during the quarter amid concerns over an FDA import alert it received for its Waluj (Maharashtra) facility in May.